2020 Dec 15 - PAS Webinar: Use of RNAscope ISH services for T-Cell Therapy Detection & Quantification
Christopher Bunker, Ph.D., MBA
Senior Director, Business Development, Advanced Cell Diagnostics
Watch Video:
Outline:
T Cell Therapy Detection and Quantification in Solid Tumors by RNAscope™ in situ hybridization.
RNAscope in situ hybridization (ISH) is the only method for specific detection of engineered CAR-T and TCR-T cell therapies in clinical trial patient biopsies. IHC is unable to differentiate engineered T cells from endogenous cells. However, RNAscope probes targeting viral untranslated regions (UTRs) common to CAR and TCR mRNAs, enable specific detection and quantification of CAR/TCR-T cells in the tumor microenvironment (TME). RNAscope UTR probes are easily multiplexed with probes to assess activation, e.g., IFNG and GZMB, as well as with T cell IHC markers, e.g. CD3, CD4, CD8 to measure T cell recruitment. These assays are used to monitor T cell therapies in post-treatment patient biopsies and in preclinical animal models of safety and efficacy.
Learning Objectives:
Key advantages of RNAscope cell therapy assays:
- Simultaneously detect CAR/TCR-T cells with cytokines, immune cell markers and target antigens
- Quantification of cell therapy tumor and stromal distribution and T cell recruitment
- Patient biopsy analysis to link cell therapy pharmacokinetics/pharmacodynamics and efficacy.
